A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Lyell Immunopharma, Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
Allogene Therapeutics
Fred Hutchinson Cancer Center
Essen Biotech
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Gilead Sciences
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Sana Biotechnology
Case Comprehensive Cancer Center
Celgene
Gilead Sciences
University of Maryland, Baltimore
Acepodia Biotech, Inc.
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Adicet Therapeutics
Peking University Cancer Hospital & Institute
University of Liverpool
Synthekine
Fred Hutchinson Cancer Center
University Hospital Heidelberg
Masonic Cancer Center, University of Minnesota
TCR2 Therapeutics
Medical College of Wisconsin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Baylor College of Medicine
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Lymphoma Study Association
M.D. Anderson Cancer Center
Pfizer
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
CTI BioPharma
Duke University
Millennium Pharmaceuticals, Inc.
The Korean Society of Pediatric Hematology Oncology
Gruppo Italiano Studio Linfomi
Lymphoma Study Association